CHF 5m more for Lunaphore!

30.08.2018 09:30, Charlotte Pichon

Tissue diagnostics innovator Lunaphore has closed its series B financing round with CHF 5.3 million, taking the medtech’s overall financing to CHF 11.3 million and positioning it well for the market launch.

Founded in 2014, Lunaphore Technologies SA is revolutionizing cancer tissue diagnostics. Its microfluid-based technology aims to perform assays much faster than standard techniques, and has attracted the attention of several investors and partners over the years. The latest financing round brought new investors to the table including Occident Group, Zürcher Kantonalbank and investment funds from Asia, Switzerland and United Kingdom.

Closing this financing round brings the company a step forward towards the commercialization of its productions and again confirms its status as a high-growth startup. The newly acquired funds will be used to enhance the market launch and drive market adoption of Lunaphore’s first product: a precision medicine solution performing ultra-rapid immunostainings, with the potential to improve patient outcomes worldwide.


Lunaphore's technology known as Fast Fluid Exchange (FFeX) will allow precise control of reaction time and help decrease the overall assay time to a few minutes.

Venturelab has supported Lunaphore from the start, with the Venture Leaders program and Venture Kick. The company reached #9 in the TOP 100 list in 2017, its fourth year in the rankings. “Participating to Venture Kick, especially attending the Kickers camp, is an excellent way to consolidate the business case and learn to be challenged, which is required also in the course of negotiations with external potential partners,” said co-founder Déborah Heintze. “Being in the TOP 100 increases highly the visibility and credibility of the company. Both channels are excellent for developing the business, and had a great impact on the company.”